Mendus
Research Mendus (IMMU.ST) on Bullrun: market cap SEK 438.04M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMMU.ST
- ExchangeXSTO
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 438.04M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 21.02M
- Free cash flow-SEK 20.80M
Valuation Snapshot
latest market cap is SEK 438.04M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 113.26M | -SEK 81.84M | n/a | -2.17 | SEK 64.66M | SEK 18.85M | SEK 585.07M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-16 | SEK 438.04M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Mendus
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mendus's market cap?
Mendus's market capitalization is SEK 438.04M.
What does Mendus do?
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel.